The Next Trip with Altasciences and DevelRX

In this podcast episode, experts from Altasciences and DevelRX examine the preclinical, clinical, and regulatory requirements and strategies that second generation psychedelics may utilize to differentiate their pharmacological profile, and strategically demonstrate efficacy and safety data that may differentiate from first generation candidates. The discussion is moderated by Altasciences' Chief Scientific Officer, Dr. Beatrice Setnik.

The potential use of psychedelics for the treatment of various CNS indications is currently under active investigation. Some researchers are already examining the use of modified chemical structures and analogs to psychedelics in an effort to produce efficacy and mitigate potential side effects of these medications. A formal drug development pathway is required when developing a drug for targeted medical use. Given the unique nature of psychedelics and their promising therapeutic potential, various strategies can be implemented to explore the efficacy and safety of these novel drugs in both the preclinical and clinical settings.